Urimar T

Urimar T Overview

Updated: 
Urimar T is a brand name medication included in the following groups of medications: Opthalmic anticholinergics, Belladonna alkaloids, tertiary amines, Other urologicals, OTHER ANTIBACTERIALS, Antidotes, Tests for gastric secretion. For more information about Urimar T see its generics Atropine, Hyoscyamine, Methenamine, Methylthioninium Chloride, Phenyl Salicylate

How was your experience with Urimar T?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking Urimar T?

What are you taking Urimar T for?

Choose one
  • Other
  • Abnormalities, Drug-induced
  • Bacteriuria
  • Bradycardia
  • Colic
  • Cyanosis
  • Cystitis
  • Drug Toxicity
  • Heart Arrest
  • Herpes Simplex
  • Hyperhidrosis
  • Intraoperative Complications
  • Irritable Bowel Syndrome
  • Lithiasis
  • Muscle Rigidity
  • Pain
  • Peptic Ulcer
  • Poisoning
  • Rhinitis
  • Sialorrhea
  • Sinoatrial Block
  • Spasm
  • Stomach Ulcer
  • Tremor
  • Urinary Bladder, Neurogenic
  • Urinary Tract Infections
  • Uveitis

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did Urimar T work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend Urimar T to a friend?

Generics

Urimar T consists of multiple generic medications. The generic medications are listed below.

Atropine

For more information on this medication choose from the list of selections below.

Hyoscyamine

For more information on this medication choose from the list of selections below.

Methenamine

For more information on this medication choose from the list of selections below.

Methylthioninium Chloride

For more information on this medication choose from the list of selections below.

Phenyl Salicylate

For more information on this medication choose from the list of selections below.

Urimar T Drug Class

Updated: 
Source